Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution by Jaime L. Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R. Digumarthy, Andrew Do, Audrey Liu, Justin F. Gainor, Jochen K. Lennerz, Timothy F. Burns, Jessica J. Lin

Get full text

Mass spectrometry methods and mathematical PK/PD model for decision tree-guided covalent drug development by Md Amin Hossain, Rutali R. Brahme, Brandon C. Miller, Jakal Amin, Marcela de Barros, Jaime L. Schneider, Jared R. Auclair, Carla Mattos, Qingping Wang, Nathalie Y. R. Agar, David J. Greenblatt, Roman Manetsch, Jeffrey N. Agar

Get full text

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib by Jaime L. Schneider, MD, PhD, Alona Muzikansky, MA, Jessica J. Lin, MD, Elizabeth A. Krueger, NP, Inga T. Lennes, MD, Joseph O. Jacobson, MD, Michael Cheng, MD, Rebecca S. Heist, MD, MPH, Zofia Piotrowska, MD, MHS, Justin F. Gainor, MD, Alice T. Shaw, MD, PhD, Ibiayi Dagogo-Jack, MD

Get full text